Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Share Options

19 Oct 2012 16:37

RNS Number : 1458P
Alliance Pharma PLC
19 October 2012
 



For immediate release

19 October 2012

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Share Options

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that on 19 October 2012 it awarded the following options over ordinary shares of the Company to certain Directors.

 

Name

Position

Number of share options awarded

Exercise price per share

Date of vesting

Percentage of issued ordinary share capital

Tony Booley

Executive Director

140,000

29.25p

19 October 2015

0.06%

Peter Butterfield

 

Executive Director

140,000

29.25p

19 October 2015

0.06%

Richard Wright

Finance Director

140,000

29.25p

19 October 2015

0.06%

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive

Richard Wright, Finance Director

www.alliancepharma.co.uk

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Oliver Cardigan

Corporate Broking: David Poutney

 

Notes to editors:

 

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

 

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

 

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBKCDNPBDDAKD
Date   Source Headline
11th Mar 20253:10 pmRNSForm 8.3 - Alliance Pharma plc
11th Mar 202512:48 pmRNSForm 8.3 - Alliance Pharma plc
11th Mar 202512:17 pmGNWForm 8.3 - [ALLIANCE PHARMA PLC - 10 03 2025] - (CGWL)
11th Mar 202510:02 amGNWForm 8.5 (EPT/RI)-Alliance Pharma plc
11th Mar 20259:47 amRNSForm 8.5 (EPT/RI) - Alliance Pharma plc
11th Mar 20257:00 amRNSForm 8.3 - Alliance Pharma plc
10th Mar 20253:00 pmBUSForm 8.3 - APH LN
10th Mar 20251:51 pmPRNForm 8.3 - Alliance Pharma Plc
10th Mar 202512:37 pmRNSForm 8.3 - Alliance Pharma PLC 10.03.2025
10th Mar 20257:58 amGNWForm 8.5 (EPT/RI)-Alliance Pharma plc
10th Mar 20257:00 amRNSFinal Increased Recommended Cash Offer
7th Mar 20256:06 pmRNSNotification of Major Holdings
7th Mar 20253:00 pmBUSForm 8.3 - APH LN
7th Mar 20251:57 pmPRNForm 8.3 - Alliance Pharma Plc
7th Mar 202511:47 amRNSForm 8.3 - Alliance Pharma PLC 07.03.2025
7th Mar 20258:41 amGNWForm 8.5 (EPT/RI) - Alliance Pharma plc
6th Mar 20253:30 pmRNSForm 8.3 - ALAPH LN
6th Mar 20253:06 pmRNSForm 8.3 - Alliance Pharma plc
6th Mar 20253:00 pmBUSForm 8.3 - APH LN
6th Mar 20251:41 pmRNSForm 8.3 - ALLIANCE PHARMA PLC
6th Mar 20251:05 pmPRNForm 8.3 - Alliance Pharma Plc
6th Mar 202512:12 pmGNWForm 8.3 - [ALLIANCE PHARMA PLC - 05 03 2025] - (CGWL)
6th Mar 202511:41 amRNSForm 8.3 - Alliance Pharma Plc
6th Mar 202511:28 amRNSForm 8.3 - Alliance Pharma PLC 06.03.2025
6th Mar 20258:27 amGNWForm 8.5 (EPT/RI) - Alliance Pharma plc
5th Mar 20253:30 pmRNSForm 8.3 - APH LN
5th Mar 20253:13 pmRNSForm 8.3 - Alliance Pharma plc
5th Mar 20252:02 pmGNWForm 8.3 - [ALLIANCE PHARMA PLC - 04 03 2025] - (CGWL)
5th Mar 20251:42 pmRNSForm 8.3 - ALLIANCE PHARMA PLC
5th Mar 202510:04 amRNSForm 8.3 - Alliance Pharma PLC 05.03.2025
5th Mar 20259:05 amGNWForm 8.5 (EPT/RI) - Alliance Pharma plc
4th Mar 20253:30 pmRNSForm 8.3 - ALAPH LN
4th Mar 20253:00 pmBUSForm 8.3 - APH LN
4th Mar 20252:33 pmRNSForm 8.3 - ALLIANCE PHARMA PLC
4th Mar 202511:43 amPRNForm 8.3 - Alliance Pharma Plc
4th Mar 202510:33 amRNSForm 8.3 - Alliance Pharma PLC 04.03.2025
4th Mar 20259:24 amGNWForm 8.5 (EPT/RI) - Alliance Pharma plc
4th Mar 20258:29 amRNSForm 8.3 - Alliance Pharma plc
3rd Mar 20253:35 pmRNSNotification of Major Holdings
3rd Mar 20253:30 pmRNSForm 8.3 - ALAPH LN
3rd Mar 20253:00 pmBUSForm 8.3 - APH LN
3rd Mar 20252:15 pmPRNForm 8.3 - Alliance Pharma Plc
3rd Mar 20257:00 amRNSForm 8.3 - Alliance Pharma plc
28th Feb 20253:30 pmRNSForm 8.3 - ALAPH LN
28th Feb 20253:25 pmRNSForm 8.3 - Alliance Pharma plc
28th Feb 20253:00 pmBUSForm 8.3 - APH LN
28th Feb 20252:38 pmRNSForm 8.3 - Alliance Pharma PLC
28th Feb 20251:24 pmPRNForm 8.3 - Alliance Pharma Plc
28th Feb 20251:20 pmRNSConfirmation of Adjournment
28th Feb 202510:06 amRNSForm 8.3 - Alliance Pharma PLC 27.02.2025

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.